The role of hydroxychloroquine sulfate in the geriatric patient with coronavirus disease 2019 (COVID-19). What is useful to know for the geriatrician?

Ciro Manzo
Azienda Sanitaria Locale Napoli 3 sud, Sant’Agnello (NA), Italy

Abstract

The role of hydroxychloroquine (HCQ) sulfate as therapeutic option in coronavirus disease 2019 (COVID-19) patients aroused great interest and hope, so much so as to authorize several studies in the world. Despite the beneficial effects demonstrated in vitro and in some case-series, doubts remain about its clinical use, so that at present more than 20 different therapeutic study protocols have been proposed. Very recently, a protocol has been authorized by the Italian Medicines Agency (AIFA), in order to evaluate the efficacy of out-of-hospital treatment with HCQ in the reducing viral load and need for hospitalization in symptomatic COVID-19 infected patients who are confined at home.

The article describes lights and shadows of HCQ therapy in the elderly and geriatric patients affected by COVID-19, and suggests that the geriatrician should use HCQ only after careful patient selection and be aware of its pharmacokinetic properties and adverse effects, before better-designed studies determine their benefit, if any, in treating COVID-19.

Introduction

Hydroxychloroquine (HCQ) sulfate is a synthetic drug belonging to the family of 4-aminoquinolines, first synthesized in 1946 by introducing a hydroxyl group at the end of the side chain of chloroquine (CQ) phosphate.1 This modification proved to reduce CQ-related toxicity without substantially changing efficacy and pharmacokinetic properties. Indeed, following oral administration, as CQ also HCQ is almost completely absorbed (with an absorption rate 70-80%) and rapidly (within 2-4 h) distributed to different tissues (lung, among these), achieving the steady state in three weeks. Variability in the absorption can influence the achievement of the steady state and more in general HCQ pharmacokinetics (30-100%), as well as its efficacy. The terminal half-life is about 40 days, although a little amount of the drug is still found in the plasma, urine, and red blood cells several years after the administration. HCQ has predominantly a renal excretion.2-6

Hydroxychloroquine in clinical practice

The experience with patients affected by rheumatic diseases (in which HCQ has been used for several decades) highlighted that it can be considered a well-tolerated treatment rarely discontinued, even in elderly patients.7-10 A dosage between 3 and 6 mg/bbodyweight/day is considered effective, while dose exceeding the recommended maximum therapeutic dosage (i.e., >6.5 mg/kg/day) is one of the most relevant risk factors for HCQ adverse events (Table 1).

In obese individuals, the dosage must be assessed considering the patient’s ideal body weight. Mostly reported adverse drug events (ADE) of HCQ include gastrointestinal symptoms and cutaneous manifestations.11 However, these events disappear with dose reduction and rarely require the treatment withdrawal. More severe and rare adverse events include retinal, neuromuscular, and cardiac impairments.

Of the known medications reported to cause QT interval prolongation, HCQ is not commonly implicated. In 2017, during the Malaria policy advisory committee meeting organized by World Health Organization (WHO) no case of arrhythmic death was reported.12 In 2018, a systematic review article reported that the risk of cardiac adverse events (conduction disorders, among these) was not quantifiable because of the lack of randomized controlled trials and observational studies investigating this association.13 Studies involving volunteers highlighted that the effect on QT interval prolongation is dependent on HCQ dose, with mean increases in QTc of 6.1 ms after a dose of 600 mg.14

In clinical practice, a baseline ECG is mandatory as well as it is prudent to correct electrolyte disorders and, where possible, avoid or minimize use of other drugs known to prolong the QT interval (see Table 1).

The use of a risk score, such as the one proposed and validated by Tisdale et al.,15 should be taken into account, in order to avoid an additive toxicity. Finally, according to the American College of Cardiology suggestions, an ECG performed 2-3 h after the second dose of HCQ, and daily thereafter, should be acquired: if QTc increases by >60 msec or absolute QTc >500 msec (or >530-550 msec if QRS >120 msec), the dose of HCQ should be reduced.

Hydroxychloroquine and severe acute respiratory syndrome-related coronavirus variant-2

In vitro studies reported that HCQ has potential to reduce the activity of severe acute respiratory syndrome-related coronavirus variant-2 (SARS-CoV-2), functioning at both the viral entry and post-entry stages of infection (Table 2).

Moreover, it is well known that HCQ can significantly decrease the production of pro-inflammatory cytokines (interleukin-6, among these), thereby counteracting the SARS-induced cytokine storm which strongly correlates with disease activity. Some clinical trials in patients with coronavirus disease 2019 (COVID-19) were then initiated, suggesting some positive results in terms of efficacy and safety. As know, all these studies had relevant bias and mixed results.21-28

According to literature review, however, very few data were available on elderly patients.

In particular, in an open-label non-randomized clinical trial published by Gautret et al. the mean age was of 45.1 years.29 In an experimental study published by Yao et al., physiologically based pharmacokinetic (PBPK) models were applied to virtual sub-
Perspective Article

Table 1. Risk factors of hydroxychloroquine-induced adverse events.

| Risk Factor                                                                 |
|----------------------------------------------------------------------------|
| 1) Female gender                                                           |
| 2) Low body weight                                                         |
| 3) Alcohol intake                                                          |
| 4) Concomitant administration of CYP3A4 inhibitors (indinavir, nelfinavir, fluconazole, ketoconazole, itraconazole, amiodarone, verapamil, diltiazem, erythromycin, clarithromycin) |
| 5) Concomitant administration of drugs that may prolong QTc interval (clarithromycin, erythromycin, amiodarone, sotalol, domperidone, haloperidol, chlorpromazine…) |
| 6) Dose exceeding the maximum therapeutic dosage (>6.5 mg/kg/day)         |
| 7) Hepatic cytochrome P450 enzyme 2D6 (CYP2D6) genetic variability, determining a poor metabolizer phenotype and an ultrarapid metabolizer phenotype |
| 8) Renal impairment                                                        |
| 9) Electrolyte disorders (mainly hypokalemia and hypo-magnesemia)         |

Table 2. Main effects of hydroxychloroquine against severe acute respiratory syndrome-related coronavirus variant-2 (in vitro).

- Deficit in the glycosylation of ACE2 receptor.²² ACE2 is expressed on surfactant-producing type 2 pneumocytes¹⁴ and is considered the most important virus cell surface receptor;
- Elevate the pH of intracellular organelles such as endosomes or endolysosomes essential for membrane fusion. In particular, this elevation blocks the transport of SARS-CoV-2 from endosomes to endolysosomes, stage necessary to release the viral genome.²¹
- Post-transcriptional modification of viral proteins.²¹

A few pharmacokinetic considerations

The most relevant and life-threatening manifestation of COVID-19 is acute respiratory distress syndrome. It has been documented that in animals, HCQ reaches lung levels of 200-700 times higher than those in the plasma,²⁹ and that in healthy volunteers, 6 mg/kg/day determined serum levels of 1.4 micromoles.³⁰ It has also been documented in vitro that the 50% cytotoxic concentrations values of HCQ were about 250 micromoles.²² However, as for today, we do not know (if not empirically) after how long such concentrations are reached in vivo. In the older patient, this knowledge is near zero.

Hydroxychloroquine and coronavirus disease 2019 in elderly and geriatric patients

Age over 70 years and comorbid conditions (hypertension, respiratory morbidity, diabetes mellitus, heart diseases, among these) are relevant risk factors for sCOVID-19.

Polypharmacology that is frequent in older geriatric patients may increase the risk for QT and QTc interval prolongation (see AIFA website).

Age-induced pharmacokinetic changes may create completely different scenarios in the older people compared to adult or young populations. Finally, some investigators suggested that the use of HCQ could worsen COVID-19, speculating that the inhibition of T-helper cell proliferation and interleukin-2 production or responsiveness induced by HCQ might raise the inflammatory response, negatively influencing patient outcomes.³¹

Conclusions

Despite a genuine enthusiasm expressed by some researchers for the potential of prescribing HCQ in the treatment of COVID-19, shadows seemed even more numerous than lights to the point that warnings are continuously increasing.³²,³³

Therefore, caution is advised especially in older and geriatric patients.

The geriatrician should use HCQ only after careful selection of patient and be aware of its pharmacokinetic properties and potential adverse effects, before better-designed studies may clearly demonstrate their benefit, if any, in treating COVID-19 in older patients.
References

1. Wallace DJ. The history of antimalarials. Lupus 1996;5:52-3.
2. Bothwell B, Forst DE. Hydroxycloroquine. In: Day RO, Forst DE, van Riel PLCM, Bresnihan B editors. Anti-rheumatic therapy: actions and outcomes. Progress in inflammation research. Birkhauser Basel; 2005. p. 81-92.
3. McLachlan AJ, Tett SE, Cutler DJ, Day RO. Bioavailability of hydroxychloroquine tablets in patients with rheumatoid arthritis. Br J Rheumatol 1994;33:235-9.
4. Tett S, Cutler D, Day R. Antimalarials in rheumatic diseases. Baillieres Clin Rheumatol 1990;4:467-89.
5. Giacomello A. Antimalarici di sintesi derivati della 4-aminocinolina. In: D’Elia S, D’Eraso E, Giacomello A, et al., eds. Farmacologia clinica reumatologica. Milan: Masson ed.; 1987. pp. 98-99.
6. Tett SE, Cutler DJ, Day RO, Brown KF. Bioavailability of hydroxychloroquine tablets in healthy volunteers. Br J Clin Pharmacol 1989;27:771-9.
7. Katz SJ, Russell AS. Re-evaluation of antimalarials in treating rheumatic diseases; reappraisal and insights into new mechanisms of action. Curr Eye Res 2011;23:278-81.
8. Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991;324:150-4.
9. Fanourakis A, Kostopoulou M, Alunno A, et al. 2019 update for the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 2019;78:736-45.
10. Manzo C. Rheumatologic concerns in an elderly patient. In: Putignano S, Cester A, Gareri P, eds. Geriatria nel territorio. Rome: Critical Medicine Publishing; 2012. pp. 685-691.
11. Haladýj E, Sikora M, Felis-Gienza A, Oleśinska M. Antimalarials - are they effective and safe in rheumatic diseases? Reumatologia 2018;56:164-73.
12. World Health Organization. Malaria policy advisory committee meeting: the cardiotoxicity of antimalarials; 22 March, 2017, pp. 6-7. Available from: http://www.who.int
13. Chatre C, Roubille F, Vernhet H, et al. Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature. Drug Saf 2018;41:919-31.
14. Juurlink DN. Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection. CMAJ 2020. [Epub ahead of print].
15. Tisdale JE, Jayes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes 2013;6:479-7.
16. Manzo C, Capuano A, Gareri P, et al. Manifestazioni neuropsichiatriche nell’anziano in corso di terapia con idrossiclorochina. Psicogeriatria 2017;2:77-81.
17. Manzo C, Gareri P, Castagna A. Psychomotor agitation following treatment with hydroxychloroquine. Drug Saf Case Rep 2017;4:6.
18. Mascolo AM, Berrino PM, Gareri P, et al. Neuropsychiatric clinical manifestations in elderly patients treated with hydroxychloroquine: a review article. Inflammopharmacol 2018 [Epub ahead of print].
19. Manzo C. Antimalarials - are they effective and safe in rheumatic diseases? Focus on the neuropsychiatric side effects. Reumatologia 2018;56:333-4.
20. Rynes RI. Antimalarials. In: Kelley WN, Harris ED Jr, Ruddy S, Sledge CB, eds. Textbook of rheumatology. Philadelphia, PA: Saunders Company; 2001. pp. 864-865.
21. Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discovery 2020;6:16.
22. Shukla MA, Wagle Shuskla A. Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues. Drugs Context 2019;8.
23. Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020. pii:cia237; doi:10.1093/cid/cia237
24. Chen J, Liu D, Liu L, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). J Zhejiang Univ (Med Sci) 2020;49. [Epub ahead of print].
25. Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv 2020. [Epub ahead of print].
26. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020. [Epub ahead of print].
27. Chinese Clinical Trial Registry. Available from: http://www.chictr.org.cn/searchproj.aspx?title=%E6%80%AF%E5%96%B9&officialname=&&secondaryid=&&applier=&&studyleadertype=&&ethicalcommitteesanction=&&sponsor=&&studyid=&&studymaintechnicalcode=&&studytype=0&&status=0&&studydesign=0&&minstudyevaluatetime=0&&maxstudyevaluatetime=0&&recruitmentstatus=0&&gender=0&&agreetosign=&&sccode=&&sourcecodes=0&&createyear=0&&ispublic=0&&btngoto=btn&verifycode=&&page=1
28. Molina JM, Delaughter C, Le Goff J, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect 2020;S0399-077X(20)30085-8. [Epub ahead of print].
29. Popert AJ. Chloroquine : a review. Rheumatology 1976;15:235-8.
30. Laaksonen AI, Koskihade V, Juva K. Dosage of antimalarial drugs for children with juvenile rheumatoid arthritis and systemic lupus erythematosus. A clinical study with determination of serum concentrations of chloroquine and hydroxychloroquine, Scand J Rheumatol 1974;3:103-8.
31. Guastalegname M, Vollone A. Could chloroquine/hydroxychloroquine be harmful in coronavirus disease 2019 (COVID-19) treatment? Clin Infect Dis 2020. [Epub ahead of print].
32. Kim AJH, Sparks JA, Liew JW, et al. A rush to judgment ? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19. Ann Intern Med 2020;March 20. [Epub ahead of print].
33. Rome BN, Avorn J. Drug evaluation during the Covid-19 pandemic. N Engl J Med 2020 [Epub ahead of print].